← Leaderboards
Antonius G Oomens
Oklahoma State University Stillwater
$1,991,770
Attributed
$1,991,770
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $421.9K · FY2013–21$500K$375K$250K$125K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$1,991,770 · 3
By mechanism
P20$1,235,116 · 1
R21$756,654 · 2
Top collaborators
No co-investigators on record.
Most similar at Oklahoma State University Stillwater
Same institution · by research overlap
- Lin Liu$25,677,420
- Hinsdale Myron$723,193
- Jerry W Ritchey$1,497,497
- Shanjana Awasthi$3,005,645
- Telugu Narasaraju$1,232,967
Others in their field
Top investigators on “Respiratory Syncytial Virus Vaccines”
- John P Moore · Weill Medical College Of Cornell Univ$32,320,703
- Natasha Bassam Halasa · Vanderbilt University Medical Center$14,704,905
- Arnold S Monto · University Of Michigan At Ann Arbor$14,469,945
- John V Williams · Vanderbilt University$13,043,731
- Jorge C Blanco · Virion Systems, Inc.$11,865,344
- Lawrence Michael Kauvar · Trellis Bioscience, Inc.$11,639,575
Research focus
Respiratory Syncytial Virus VaccinesResponseChildImmune ResponseCessation Of LifeBaseRespiratory Syncytial VirusIn VivoVaccinesVirusImmunityViral AntigensLung DiseasesVirionMorphologyElderlyAttenuated VaccinesAttenuated Live Virus VaccineLungAttenuatedCellsLaboratoriesInactivated VaccinesInfancy
Grant awards (9)
An authentic RSV virus-like particle vaccine to achieve broad and long-lasting protection$184,761
R21 · FY2021 · AI · contact PI
An authentic RSV virus-like particle vaccine to achieve broad and long-lasting protection$214,721
R21 · FY2020 · AI · contact PI
A self-limited live RSV vaccine inducing anti- pre-fusion F antibodies$182,250
R21 · FY2018 · AI · contact PI
Development of an RSV Vaccine by Molecular Manipulation of the Viral Matrix Prot$246,939
P20 · FY2017 · GM · contact PI
A self-limited live RSV vaccine inducing anti- pre-fusion F antibodies$174,922
R21 · FY2017 · AI · contact PI
Development of an RSV Vaccine by Molecular Manipulation of the Viral Matrix Prot$246,940
P20 · FY2016 · GM · contact PI
Development of an RSV Vaccine by Molecular Manipulation of the Viral Matrix Prot$246,941
P20 · FY2015 · GM · contact PI
Development of an RSV Vaccine by Molecular Manipulation of the Viral Matrix Prot$246,942
P20 · FY2014 · GM · contact PI
Development of an RSV Vaccine by Molecular Manipulation of the Viral Matrix Prot$247,354
P20 · FY2013 · GM · contact PI